CL2018002787A1 - Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. - Google Patents

Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.

Info

Publication number
CL2018002787A1
CL2018002787A1 CL2018002787A CL2018002787A CL2018002787A1 CL 2018002787 A1 CL2018002787 A1 CL 2018002787A1 CL 2018002787 A CL2018002787 A CL 2018002787A CL 2018002787 A CL2018002787 A CL 2018002787A CL 2018002787 A1 CL2018002787 A1 CL 2018002787A1
Authority
CL
Chile
Prior art keywords
treatment
methods
compositions
compounds
substituted aminopurine
Prior art date
Application number
CL2018002787A
Other languages
English (en)
Spanish (es)
Inventor
Robert Hubbard
Heather Raymon
John F Boylan
Gordon L Bray
Ellen Filvaroff
David Mikolon
Tao Shi
Tam M Tran
Toshiya Tsuji
Lilly L Wong
Suichan Xu
Dan Zhu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of CL2018002787A1 publication Critical patent/CL2018002787A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2018002787A 2016-04-01 2018-09-28 Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. CL2018002787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
CL2018002787A1 true CL2018002787A1 (es) 2019-01-18

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002787A CL2018002787A1 (es) 2016-04-01 2018-09-28 Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.

Country Status (15)

Country Link
US (1) US10576085B2 (enExample)
EP (1) EP3436018A4 (enExample)
JP (1) JP7014731B2 (enExample)
KR (1) KR102356433B1 (enExample)
CN (1) CN109069512B (enExample)
AU (1) AU2017241837B2 (enExample)
BR (1) BR112018070163A2 (enExample)
CA (1) CA3018986A1 (enExample)
CL (1) CL2018002787A1 (enExample)
EA (1) EA039392B1 (enExample)
IL (1) IL262007B2 (enExample)
MX (1) MX379513B (enExample)
NZ (1) NZ746554A (enExample)
SG (2) SG11201808388QA (enExample)
WO (1) WO2017173206A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
MX379439B (es) 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) * 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
AU2020257207B2 (en) * 2019-04-16 2026-06-04 Vivace Therapeutics, Inc. Bicyclic compounds
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
CN115279368B (zh) * 2019-11-20 2024-05-24 维瓦斯治疗公司 杂芳基化合物
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途
EP4703725A1 (en) 2024-08-29 2026-03-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式p−38キナーゼ阻害剤
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
DK3204386T3 (da) * 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
CN115131834A (zh) * 2015-08-13 2022-09-30 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
MX379439B (es) * 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.

Also Published As

Publication number Publication date
EA039392B1 (ru) 2022-01-21
JP2019510066A (ja) 2019-04-11
WO2017173206A1 (en) 2017-10-05
IL262007B2 (en) 2023-04-01
IL262007A (en) 2018-10-31
SG11201808388QA (en) 2018-10-30
AU2017241837A1 (en) 2018-10-25
MX2018011992A (es) 2019-01-24
CN109069512A (zh) 2018-12-21
AU2017241837B2 (en) 2021-07-22
EP3436018A4 (en) 2019-11-13
KR20180126497A (ko) 2018-11-27
SG10202009589UA (en) 2020-10-29
US20170281633A1 (en) 2017-10-05
US10576085B2 (en) 2020-03-03
JP7014731B2 (ja) 2022-02-01
EA201892229A1 (ru) 2019-03-29
IL262007B (en) 2022-12-01
EP3436018A1 (en) 2019-02-06
BR112018070163A2 (pt) 2019-01-29
NZ746554A (en) 2023-03-31
CN109069512B (zh) 2022-06-14
CA3018986A1 (en) 2017-10-05
KR102356433B1 (ko) 2022-01-27
MX379513B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2022013619A (es) Compuestos de 2,4-dioxopirimidina que inhiben cd73.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
PE20200733A1 (es) Inhibidores de kras g 12c y metodos para su uso
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2017001336A1 (es) Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos
PH12017501879A1 (en) Methods for treating cancer
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2018001315A (es) Inhibidores de fucosidasa.